6391 - 6400 of 7942 Results
Title
Year
-
OPENTitle: Neurogenesis in Cancun: where science meets the seaJournal Name: DevelopmentPublisher: The Company of BiologistsVol: 143Issue #: 10Start Page: 1649End Page: 1654Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1242/dev.138412Best OA location URL: https://dev.biologists.org/content/develop/143/10/1649.full.pdfCitation Count: 0
-
RESTRICTEDTitle: Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseasesJournal Name: Expert Opinion on Therapeutic TargetsPublisher: Informa UK LimitedVol: 20Issue #: 10Start Page: 1237End Page: 1245Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1080/14728222.2016.1182990Best OA location URL: https://europepmc.org/articles/pmc5315368?pdf=renderCitation Count: 42
-
OPENTitle: Analysis of Mitochondrial haemoglobin in Parkinson's disease brainJournal Name: MitochondrionPublisher: Elsevier BVVol: 29Issue #:Start Page: 45End Page: 52Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.mito.2016.05.001Best OA location URL: https://doi.org/10.1016/j.mito.2016.05.001Citation Count: 24
- Enabling breakthroughs in Parkinson’s disease with wearable technologies and big data analytics2016OPENTitle: Enabling breakthroughs in Parkinson’s disease with wearable technologies and big data analyticsJournal Name: mHealthPublisher: AME Publishing CompanyVol: 2Issue #:Start Page: 20End Page: 20Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.21037/mhealth.2016.04.02Best OA location URL: https://europepmc.org/articles/pmc5344108?pdf=renderCitation Count: 31
-
OPENTitle: LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesiasJournal Name: Molecular BrainPublisher: Springer Science and Business Media LLCVol: 9Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s13041-016-0234-2Best OA location URL: https://molecularbrain.biomedcentral.com/track/pdf/10.1186/s13041-016-0234-2Citation Count: 11
-
OPENTitle: Normative data for subcortical regional volumes over the lifetime of the adult human brainJournal Name: NeuroImagePublisher: Elsevier BVVol: 137Issue #:Start Page: 9End Page: 20Publication Date:Open Access(OA) Status: OPENLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1016/j.neuroimage.2016.05.016Best OA location URL: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdfCitation Count: 114
-
OPENTitle: Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's diseaseJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 45Issue #:Start Page: 212.e13End Page: 212.e17Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2016.04.023Best OA location URL: http://hdl.handle.net/20.500.11794/13593Citation Count: 47
-
RESTRICTEDTitle: How can rAAV‐α‐synuclein and the fibril α‐synuclein models advance our understanding of Parkinson's disease?Journal Name: Journal of NeurochemistryPublisher: WileyVol: 139Issue #: S1Start Page: 131End Page: 155Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1111/jnc.13627Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jnc.13627Citation Count: 81
-
OPENTitle: Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer’s Disease With Aggression or Agitation: The CitAD Randomized Clinical TrialJournal Name: American Journal of PsychiatryPublisher: American Psychiatric Association PublishingVol: 173Issue #: 5Start Page: 465End Page: 472Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1176/appi.ajp.2015.15050648Best OA location URL: https://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.15050648Citation Count: 82
-
RESTRICTEDTitle: The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of actionJournal Name: Drug Discovery TodayPublisher: Elsevier BVVol: 21Issue #: 5Start Page: 802End Page: 818Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.drudis.2016.01.013Best OA location URL: https://doi.org/10.1016/j.drudis.2016.01.013Citation Count: 246